文献速递神经介入DSACTMR

经静脉栓塞作为最后手段治疗破裂脑动静脉畸形的安全性与疗效:一项前瞻性单臂研究

Safety and Efficacy of Transvenous Embolization of Ruptured Brain Arteriovenous Malformations as a Last Resort: A Prospective Single-Arm Study.
PubMed 文献 · AJNR Am J Neuroradiol · 2019-09-19

本前瞻性单臂研究纳入21例2016年11月至2018年11月间接受经静脉栓塞的破裂脑动静脉畸形患者,Spetzler-Martin分级I级3例、II级4例、III级11例、IV级3例;19例技术可行者中16例(84%)栓塞后即刻完全闭塞,1例(5%)小残余在13个月随访时完全闭塞;出血5例、梗死1例,mRS≤2比例从术前57.1%(12/21)升至1个月随访66.7%(14/21),死亡率和致残率均为4.8%(1/21);作者认为经静脉栓塞仅可用于高度选择的出血性动静脉畸形,不应作为一线治疗。

要点

  • 仅适用于高度选择的破裂脑动静脉畸形,不应作为一线治疗。
  • 技术可行者栓塞后即刻完全闭塞率84%(16/19)。
  • 术后1个月内出血5例、梗死1例,死亡率和致残率均为4.8%。

核心结论

  • 经静脉栓塞仅可在高度选择的出血性动静脉畸形中施行,具有较高的完全闭塞率、改善的功能结局和可接受的致残率与死亡率,但不应视为一线治疗。

研究设计与样本

  • 前瞻性单臂研究,连续纳入21例接受经静脉栓塞的破裂脑动静脉畸形患者,随访时间为2016年11月至2018年11月。
  • Spetzler-Martin分级:I级3例(14.3%),II级4例(19.0%),III级11例(52.4%),IV级3例(14.3%)。
  • 完全闭塞率由6个月随访DSA图像计算,术后1个月内采用CT和MR成像评估栓塞后出血和梗死,采用mRS评估功能结局。

诊断标准与关键数值

  • 栓塞后即刻完全闭塞:19例技术可行患者中16例(84%)。
  • 1例(5%)治疗后小残余在13个月随访时完全闭塞。

临床应用与阅片要点

  • 栓塞后1个月内需用CT和MR成像评估出血和梗死。
  • 功能结局用mRS评估,mRS≤2比例从栓塞前57.1%(12/21)升至1个月随访66.7%(14/21)。
  • 作者认为经静脉栓塞仅可用于高度选择的出血性动静脉畸形,不应作为一线治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: The efficacy and safety of transvenous embolization for brain arteriovenous malformations remains unclear, given the very limited number of cases reported. This prospective study was performed to assess this technique in ruptured AVMs.

MATERIALS AND METHODS: Twenty-one consecutive patients with ruptured brain AVMs who underwent transvenous embolization were prospectively followed between November 2016 and November 2018. The Spetzler-Martin grade was I in 3 AVMs (14.3%), II in four (19.0%), III in eleven (52.4%), and IV in three (14.3%). The complete AVM occlusion rate was calculated from 6-month follow-up DSA images. Occurrence of hemorrhage and infarction after embolization was evaluated using CT and MR imaging within 1 month after the operation. The mRS was used to assess the functional outcomes.

RESULTS: Complete AVM nidus obliteration was shown in 16 (84%) of 19 patients with technically feasible AVMs immediately after embolization. One (5%) patient with a small residual nidus after treatment showed complete obliteration at 13-month follow-up. There were 5 hemorrhages and 1 infarction; 4 patients' symptoms improved gradually. The percentage of cases with mRS ≤ 2 rose from 57.1% (12/21) before embolization to 66.7% (14/21) at 1-month follow-up. Both the morbidity and mortality rates were 4.8% (1/21).

CONCLUSIONS: Transvenous embolization can be performed only in highly selected hemorrhagic brain AVMs with high complete obliteration rates, improved functional outcomes, and acceptable morbidity and mortality rates, but it should not be considered as a first-line treatment.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. He Y, Ding Y, Bai W, et al. Safety and Efficacy of Transvenous Embolization of Ruptured Brain Arteriovenous Malformations as a Last Resort: A Prospective Single-Arm Study. AJNR Am J Neuroradiol. 2019. PMID: 31537516. doi:10.3174/ajnr.A6197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。